Skip to Sidebar Skip to Content

NCL Technology Ventures

London specialist healthcare investor funding early-stage therapeutics, medtech and digital health companies

  • Venture capital
  • London
Type
Venture capital
Based in
London
Stages
Pre-seed, Seed, Series A, Series B+
Sector focus
Fintech, Healthtech
Cheque size
€1.5M–€3M
Fund size
Undisclosed
Founded
2015

NCL Investment Management, the trading name of NCL Technology Ventures Ltd, is a specialist healthcare investor authorised by the Financial Conduct Authority. It provides equity and operational support to early-stage companies whose technologies aim to prevent, treat or cure disease. Areas of interest include immunology and autoimmune conditions, infectious disease, oncology, women's health and digital health. Its portfolio spans therapeutics and medtech businesses such as TC BioPharm, Centauri Therapeutics, Emteq Labs, Ampersand Health and Curesponse. Managing Partner Jerry Biggs set up the investment management business in 2015. The firm is headquartered in London, with a satellite office in New Haven, Connecticut.

Add this profile to your website

Show this card on your own site. It reads “As seen on EP+” and links back to this page.

Paste it anywhere your site accepts HTML. Is this your organisation? Request an update if the card is out of date.

← All investors · Is this your organisation? Request an update

More investors in the directory

Subscribe to Newsletter

UK startup news, founder stories and funding insight, straight to your inbox every week. Free.